ChemicalBook

152459-95-5(Imatinib) Product Description

Imatinib Structure152459-95-5
CAS No.152459-95-5
Chemical Name:Imatinib
CBNumber:CB7370890
Molecular Formula:C29H31N7O
Formula Weight:493.6
MOL File:Mol file
Imatinib Synonyms:
Imatinib (4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
Imatinib free base
Veenat
IMatinib(STI571)
Imantinib base
4-(4-Methyl-piperazin-1-ylMethyl)-N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaM
IMatinib-D4
IMatinib (Gleevec)

Imatinib Property

Melting point: 208-210°C (dec.)
Density  1?+-.0.06 g/cm3(Predicted)
storage temp.  Keep in dark place,Sealed in dry,Store in freezer, under -20°C
solubility  DMSO (Slightly, Heated), Methanol (Slightly, Heated)
pka pKa1 8.07; pKa2 3.73; pKa3 2.56; pKa4 1.52(at 25℃)
form  Solid
color  White to Pale Beige
Merck  14,4902
CAS DataBase Reference 152459-95-5(CAS DataBase Reference)

Safety

Safety Statements : 24/25
RTECS : CV5585673
HS Code : 29339900

Imatinib Suppliers

Global( 612)Suppliers     
SupplierTelEmailCountryProdListAdvantage
Guangzhou Isun Pharmaceutical Co., Ltd 020-39119399isunpharm@qq.comChina 4428 55
AnHui HaiKang Pharmaceutical Co., Ltd. 0556-5800026melrose@worldpharma.cnChina 223 55
Jinan Xinzheng Pharmaceutical Technology Co., Ltd. 0531-88798968yin3684895@126.comChina 171 58
Hubei Haiyue Biotechnology Co., Ltd  haiyue1682022@163.comChina 251 58
Hangzhou Bingochem Co., Ltd. 0571-8512-5372sales@bingochem.comChina 21673 58
Xuzhou Maikai Biotechnology Co., Ltd.  SVP01@magicbiotech.cnChina 508 58
Wuhan Hongde Yuexin Pharmaceutical Technology Co., Ltd 02783850058whhdyxchem027@sina.comChina 2730 58
Artis Biotech Co. Ltd. 19138486554sales@artisbio.comChina 2964 58
152459-95-5(Imatinib) Related Search:
Imatinib (4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide Imatinib free base Veenat IMatinib(STI571) Imantinib base 4-(4-Methyl-piperazin-1-ylMethyl)-N-[4-Methyl-3-(4-pyridin-3-yl-pyriMidin-2-ylaM IMatinib-D4 IMatinib (Gleevec) 4-[(4-Methylpiperazin-1-yl)Methyl]-N-[4-Methyl-3- 1-Methyl-4-(4-((4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)carbaMoyl)benzyl)piperazine 1,4-dioxide 4,4'-(piperazine-1,4-diylbis(Methylene))bis(N-(4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)benzaMide) 4-Methyl-1-(4-((4-Methyl-3-((4-(pyridin-3-yl)pyriMidin-2-yl)aMino)phenyl)carbaMoyl)benzyl)piperazine 1-oxide CGP-57148B, STI-571 IMatinib SynonyMs 4-[(4-Methylpiperazin-1-yl)Methyl]-N-[4-Methyl-3-[(4-pyridin-3-ylpyriMidin-2-yl)aMino]phenyl]benzaMide 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide CGP057148B ST-1571 IMA-3 IMATINIB IMATINIB-D3 IMATINIB 99+% Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- AKOS 91378 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide methanesulfonate Imatinib, ≥99%,HPLC Imatinib,Gleevec,Glivec,STI-571 Imatinib 152459-95-5 CS-1955 Imatinib Mesylate Impurity 5 Imatinib> Imatinib USP/EP/BP Imatinib Raw 4-(4-Methyl-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamid e(IMATINIB FREE BASE) Imatinib Base (IMB-1) 4-[(4-methyl: -1-piperazininyl)methyl]-N[4-methyl-3-[[4- {3-pyridinyl)-2-pyrimidinyl]ammo]pheny1}benzamide(For Imatinib Mesylate API) Imatinib API & intermediates N-[4-Methyl-3-[[4-(3-pyridyl)-2-pyrimidyl]amino]phenyl]-4-[(4-methyl-1-piperazinyl)methyl]benzamide 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE Imatinib Mesilate matinib lmatinib Ethane,1-(2-bromoethoxy)-2-(6-methoxyethoxy)- 4-[(4-Methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide (Imatinib base) 152459-95-5 1144803-18-1 152459-95-9 C29H31N7O API Antineoplastic Anti-cancer & immunity GLEVEEC Aromatics Heterocycles Impurities Intermediates & Fine Chemicals Pharmaceuticals Pharmaceutical intermediate Imatinib Inhibitors
Copyright 2017 © ChemicalBook. All rights reserved